MedPath

Clopidogrel of loading dosage to treat acute ischaemic stroke in China (CLASS-CHINA)

Completed
Conditions
Acute ischaemic stroke
Circulatory System
Registration Number
ISRCTN07057952
Lead Sponsor
Jinan University Guangzhou (China)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
600
Inclusion Criteria

1. Aged 18-80 years
2. Ischemic stroke (IS) within 48 hrs with evidence of computerised tomography (CT) or magnetic resonance imaging (MRI)
3. Satisfying the criteria of partial anterior circulation infarction (PACI) of Oxfordshire Community Stroke Project (OCSP) classification, and large artery atherothrombosis (LAA) of TOAST (the Trial of Org 10172 in Acute Stroke Treatment) classification
4. Informed consent of patient

Exclusion Criteria

1. Patients planned for thrombolysis
2. Any of the following:
2.1. Cardiogenic cerebral embolism
2.2. Lacuna cerebral infarction
2.3. Total anterior circulation cerebral infarction
2.4. Posterior circulation cerebral infarction
2.5. Cerebral infarction of the etiology rather than atherothrombosis and unidentified etiology
3. History of allergic reaction to clopidogrel
4. Patients regularly took oral anticoagulants (OAC), heparin or molecular weight heparin (LMWH), thienopyridine (clopidogrel or ticlopidine), aspirin (acetylsalicylic acid) >50 mg/d, Aggrenox® before the onset; or patients who need long-term use of drugs that affect platelet functions
5. History of bleeding disorders; clinically significant or persistent thrompocytopenia or neutropenia.
6. Women who are pregnant or breast-feeding
7. Patients with planned surgery within the next 1 month; with a recent operation or trauma history.
8. Severe systematic disorders i.e. heart, lung, liver, kidney diseases, or malignant tumor; or severe gastrointestinal disorder affecting the absorption of drug
9. Enrolled in other clinical trials within the past 3 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Stroke recurrence or SIP (evaluated by the National Institutes of Health Stroke Scale [NIHSS]) within 7days.
Secondary Outcome Measures
NameTimeMethod
1. Death or dependence (modified Rankin Scale [mRS] >=3) at 28 and 90 days <br>2. Death or stroke recurrence within 28 days <br>3. Stroke recurrence, acute myocardial infarction or vascular death with 28 days <br>4. Bleeding: Life-threatening bleeding, major bleeding and minor bleeding
© Copyright 2025. All Rights Reserved by MedPath